About Index Trending news
Analyze
Top 50 Pricing
Regeneron

Regeneron

Work at Regeneron? Add yourself to this profile

Regeneron

Official Twitter channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here our site

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO equity
$8,900,000
Health and Human Services
Employees

Team size

1000+
Locations
HQ
Headquarters
Xconomy

Regeneron: It’s Still Wait Until 2017 For Big Heart Drug Study

Xconomy

Weeks After Deal, FDA Slaps Clinical Hold on Regeneron/Teva Pain Drug

Xconomy

Ocular Therapeutix Inks Licensing Deal With Regeneron For Wet AMD

Xconomy

Regeneron, in Pain Drug Race With Pfizer & Lilly, Gets $250M From Teva

$8,900,000 Post-IPO equity
yahoo

Regeneron Announces Agreement with BARDA for the Manufacturing and Testing of New Antibodies Against MERS Virus

The Motley Fool

3 Biotech Stocks to Buy Now for the Long Haul

The Motley Fool

3 Biotech Stocks to Buy If the Market Crashes

The Motley Fool

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche

New York Times Bits

Regeneron Pharmaceuticals to Sponsor Science Talent Search

Education Awards
The Motley Fool

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Ophthotech

Health Stock markets Earnings
The Motley Fool

3 Stocks You Can Buy and Hold Forever

Stock markets Technology
The Motley Fool

Eylea's Growth Propels Regeneron Pharmaceuticals Inc Shares Higher

The Motley Fool

9 Figures That Sum Up Regeneron Pharmaceuticals' First Quarter

The Motley Fool

Regeneron Pharmaceuticals Inc Has a Lot to Prove on May 5

The Motley Fool

3 Stocks to Buy in a Crashing Market

The Motley Fool

Regeneron's Bold Bet on the Future of Medicine

Xconomy

CRISPR Developer Intellia Deals With Regeneron, Jumps Into IPO Queue

The Motley Fool

This Amgen News Could Be a Game-Changer in its Fight Against Sanofi and Regeneron Pharmaceuticals

The Motley Fool

Better Buy: Regeneron Pharmaceuticals, Inc. vs. Amgen

Earnings Health Stock markets
The Motley Fool

Why Regeneron Pharmaceuticals, Tronox, and Office Depot Jumped Today